Home/ Supplements/ Niacin/ Endur-Amide Sustained Release Niacinamid...

Endur-Amide Sustained Release Niacinamide 250 mg

product on market Tablet or Pill EP Safety: 60/100
60/100

Review before taking

  • Niacinamide: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

What the Evidence Says

✨ AI-generated · Qwen 3.6 · grounded in 1 source · methodology

Niacinamide is used to support skin health and cellular energy metabolism, though evidence for specific systemic benefits is limited. Due to a safety score of 60, potential concerns regarding dosage and individual tolerance should be noted. This ingredient profile lacks extensive clinical backing for the specific sustained-release formulation.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacinamide: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

✨ AI-generated · Qwen 3.6 · grounded in 2 sources · methodology

This product received a low safety score because it contains 250mg of Niacinamide, which is over seven times the recommended upper limit for daily intake.

Label

Product Label

Label for Endur-Amide Sustained Release Niacinamide 250 mg
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
Vitamin
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

250 mg (1250% DV)
Exceeds UL by 7.1× (UL: 35 mg) 196 studies (A:5, B:63)

Other Ingredients

Carnauba Wax Vegetable Stearine Magnesium Stearate Silica
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

DIRECTIONS: As a dietary supplement, take one to three tablets daily with food or drink. Do not exceed recommended dose without consulting a physician.

Warnings & Precautions

Keep out of reach of children

Formulation Notes

(Nicotinamide)

Contains no salt, sugar, starch, preservatives, artificial color or flavorings.

(CONTAINS VEGETABLE STEARINE FROM SOYBEAN OIL)

Additional Information

These tablets are specially manufactured to release the dietary ingredient continuously over a 6-8 hour period.

16605

Store at room temperature.

EP

Metadata

Product Details

UPC / SKU7 29135 16605 3
DSLD Entry Date2013-01-25
Product TypeVitamin
FormTablet or Pill
BrandEP
DSLD ID17756
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

Rezistaf
LifeLink · Tablet or Pill
100
Coenzymated B-3 25 mg
Source Naturals · Tablet or Pill
100
Vitamin B Complex
Simply Supplements · Tablet or Pill
100
Test X180 Boost
Force Factor · Tablet or Pill
100
8-Hour Alert
MHP Maximum Human Performance · Tablet or Pill
100
View all Niacin products →
Niacin research Best Niacin All Niacin products More from EP View on NIH DSLD →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.